

| Каталожный номер | DY286018 |
|---|---|
| Тип образца | Plasma, Serum |
| Чувствительность | 0.156 μg/ml |
| Диапазон | 0.31-5 μg/mL |
| Номер доступа | P04626 |
| Применения | ELISA |
| Метод обнаружения | Colorimetric |
| Тип анализа | Quantitative |
| Восстановление | 80-120% |
| Доставка | 2-8 ℃ |
| Устойчивость и хранение | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| Характеристики | Disitamab |
| Альтернативные названия | RC48-0, Disitamab Vedotin, 2185868-98-6 |
| Фон | Receptor tyrosine-protein kinase erbB-2 (Disitamab) is a ~137 kDa protein. Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. |
| Ссылки | 1. Deeks ED. Disitamab Vedotin: First Approval. Drugs. 2021;81(16):1929-1935. [DY286018] 2. Jiang J, et al. Preclinical safety profile of disitamab vedotin: a novel anti-HER2 antibody conjugated with MMAE. Toxicol Lett. 2020;324:30-37. [DY286018] 3. Huang L, Wang R, Xie K, et al. A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation. Breast Cancer Res Treat. 2022;191(1):51-61. [DY286018] |
| Примечание | For Research Use Only. |

Standard Curve of Disitamab ELISA Kit




Свяжитесь с нами для индивидуальных предложений, оптовых запросов и других вопросов.
Почта: [email protected]


+86-027-65523339
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский